Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 2/20 | 0.37 |
| ▸ | DNTT | P04053 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11154315 | 1.00 | ABCB11 (0.44) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| SCHEMBL11152597 | 1.00 | ABCB11 (0.44) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| SCHEMBL11157946 | 1.00 | ABCB11 (0.44) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| SCHEMBL11166645 | 1.00 | ABCB11 (0.44) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| SCHEMBL11469717 | 1.00 | ABCB11 (0.44) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| SCHEMBL11156466 | 1.00 | ABCB11 (0.44) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| SCHEMBL11158299 | 1.00 | ABCB11 (0.44) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| SCHEMBL6662591 | 0.93 | ABCB11 (0.40) | ABCB11LMNAMAPTMAPK1CYP4F2 | |
| SCHEMBL11156331 | 0.91 | TERT (0.42) | LMNAMAPTPOLB | |
| SCHEMBL11156333 | 0.91 | TERT (0.42) | LMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218608-A1 | NEW STRATEGY FOR TREATING PANCREATIC CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2023-07-13 | — | — | US | claimed |
| EP-4168006-A1 | NEW STRATEGY FOR TREATING PANCREATIC CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-04-26 | — | — | EP | claimed |
| WO-2021255204-A1 | NEW STRATEGY FOR TREATING PANCREATIC CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-12-23 | — | — | WO | claimed |
| US-20200330400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | BERG LLC | 2020-10-22 | — | — | US | claimed |
| WO-2017161205-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | BERG LLC (US) | 2017-09-21 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | claimed |
| EP-2445506-B1 | THE USE OF SPINOSYNS AND SPINOSYN COMPOSITIONS AGAINST DISEASES CAUSED BY PROTOZOANS, VIRAL INFECTIONS AND CANCER | ENTARCO SA (GR) | 2014-12-31 | — | — | EP | claimed |
| WO-2014018801-A1 | DIAGNOSIS AND TREATMENT OF CANCER USING DIFFERENTIALLY EXPRESSED STARVATION MARKERS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-01-30 | — | — | WO | claimed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | claimed |
| US-20030202950-A1 | Reduction of hair growth | THE GILLETTE COMPANY | 2003-10-30 | — | — | US | claimed |
| US-20030153619-A1 | Applying on the skin, inhibiting fatty acid metabolism, using adriamycin, or enzyme inhibitors, dermatology | GILLETTE COMPANY, THE | 2003-08-14 | — | — | US | claimed |
| WO-2003063810-A2 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2003-08-07 | — | — | WO | claimed |
| EP-0412211-A1 | Cancer therapy system | THERAPEUTICAL SYSTEMS CORPORATION (US) | 1991-02-13 | — | — | EP | claimed |
| US-4935450-A | Cancer therapy system for effecting oncolysis of malignant neoplasms | THERAPEUTICAL SYSTEMS CORPORATION (US) | 1990-06-19 | — | — | US | claimed |
| US-4724230-A | Method for producing oncolysis | THERAPEUTICAL SYSTEMS CORP. (US) | 1988-02-09 | — | — | US | claimed |
| EP-0115406-B1 | PROCESS FOR PRODUCTION OF METHYL 2-TETRADECYLGYCIDATE | McNeilab, Inc. (US) | 1986-10-29 | — | — | EP | claimed |
| US-4499294-A | Process for production of methyl 2-tetradecylgycidate | MCNEILAB, INC. (US) | 1985-02-12 | — | — | US | claimed |
| EP-0115406-A1 | Process for production of methyl 2-tetradecylgycidate | McNeilab, Inc. (US) | 1984-08-08 | — | — | EP | claimed |
| US-4370343-A | GLYCIDIC OR THIOGLYCIDIC ACID DEPRIVATIVES | MCNEILAB, INC. (US) | 1983-01-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | CPT1B, CPT2, CPT1A | ABCB11 1461/4885LMNA 1667/4885MAPT 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.